JOMPAC
Journal of Medicine and Palliative Care

Journal of Medicine and Palliative Care (JOMPAC) is an open access scientific journal with independent, unbiased, and double-blind review under international guidelines. The purpose of JOMPAC is to contribute to the literature by publishing articles on health sciences and medicine.

eISSN: 2717-7505
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Treatment selection for T4 laryngeal cancer: is organ-preserving approach possible with chemoradiotherapy or is multimodality treatment more effective?
Abstract
Aims: Organ-preserving approach is recommended as an evidence-based treatment option for advanced laryngeal cancer (LC) with similar survival results. However, the organ-preserving approach in T4 disease is controversial, and surgical treatment is primarily preferred. Today, chemoradiotherapy (CRT) is applied to T4 LC patients who are inoperable for medical or surgical reasons and upon the request of the patient who refuses the recommended surgical treatment. The aim of this study was to evaluate the treatment outcomes in patients with T4 LC who underwent CRT for these conditions and received adjuvant radiotherapy (RT)/CRT as the standard treatment regimen after surgery.
Methods: A retrospective review of T4 LC patients treated with CRT (17 patients) and adjuvant RT/CRT (26 patients) between 2015 and 2021 was conducted. Overall survival (OS), local regional recurrence-free survival (LRRFS), and disease-free survival (DFS) were compared between the groups. The organ preservation rate was determined for the CRT group.
Results: The median follow-up time for the entire cohort was 41 months, the 5-y OS, LRRFS, and DFS were 55.9%, 51.4%, and 51.9%, respectively. Statistically significant difference was found between the treatment groups in terms of 5-y OS, LRRFS, and DFS rates, and survival was found to be decreased in the CRT group (35.3% vs. 70.2%, p=0.007; 22.1% vs. 75.1%, p= 0.001; 22.1% vs. 75.7%, p=0.001). With respect to other clinicopathological factors, age was the only significant factor in on OS in multivariate analysis, whereas tumor size, nodal stage, and ECE (in the postoperative RT group, except LRRFS) were linked with OS, LRRFS, and DFS rates. Among the patients who underwent CRT, OS was found to be better in the group applied due to the patient’s request compared to the patients referred for RT due to medical or surgical inoperability, and in multivariate analysis, the indication for RT remained an independent predictor of OS. In addition, the 3-y organ preservation rate was 81.5% in the CRT group.
Conclusion: The surgical arm had statistically significantly superior results in terms of OS, LRRFS, DFS compared to the CRT group. However, it is also noteworthy that OS was better in cases where RT is applied at the patient’s request without inoperable disease. In addition, laryngeal protection was observed to a large extent in the CRT arm.

Keywords : Laryngeal cancer, advanced stage, organ preservation, radiotherapy, laryngectomy, treatment outcome

Download Article


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA CancerJ Clin. 2016;66(1):7-30. doi:10.3322/caac.21332
2. American Society of Clinical Oncology, Pfister DG, Laurie SA,et al. American Society of Clinical Oncology clinical practiceguideline for the use of larynx-preservation strategies in thetreatment of laryngeal cancer. J Clin Oncol. 2006;24(22):3693-3704. doi:10.1200/JCO.2006.07.4559
3. Department of Veterans Affairs Laryngeal Cancer Study Group,Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiationcompared with surgery plus radiation in patients with advancedlaryngeal cancer. N Engl J Med. 1991;324(24):1685-1690.doi:10.1056/NEJM199106133242402
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrentchemotherapy and radiotherapy for organ preservation inadvanced laryngeal cancer. N Engl J Med. 2003;349(22):2091-2098. doi:10.1056/NEJMoa031317
5. Terrell JE, Fisher SG, Wolf GT. Long-term quality of life aftertreatment of laryngeal cancer. The Veterans Affairs LaryngealCancer Study Group. Arch Otolaryngol Head Neck Surg.1998;124(9):964-971. doi:10.1001/archotol.124.9.964
6. Richard JM, Sancho-Garnier H, Pessey JJ, et al. Randomized trialof induction chemotherapy in larynx carcinoma. Oral Oncol.1998;34(3):224-228. doi:10.1016/s1368-8375(97)00090-0
7. World Medical Association.. World Medical AssociationDeclaration of Helsinki. Ethical principles for medicalresearch involving human subjects. Bull World Health Organ.2001;79(4):373-374.
8. Forastiere AA, Zhang Q, Weber RS, et al. Long-term results ofRTOG 91-11: a comparison of three nonsurgical treatmentstrategies to preserve the larynx in patients with locally advancedlarynx cancer. J Clin Oncol. 2013;31(7):845-852. doi:10.1200/JCO.2012.43.6097
9. Patel SA, Qureshi MM, Dyer MA, Jalisi S, Grillone G, TruongMT. Comparing surgical and nonsurgical larynx-preservingtreatments with total laryngectomy for locally advanced laryngealcancer. Cancer. 2019;125(19):3367-3377. doi:10.1002/cncr.32292
10. Stokes WA, Jones BL, Bhatia S, et al. A comparison of overallsurvival for patients with T4 larynx cancer treated with surgicalversus organ-preservation approaches: A National CancerData Base analysis. Cancer. 2017;123(4):600-608. doi:10.1002/cncr.30382
11. Brandstorp-Boesen J, Falk RS, Boysen M, Brøndbo K. Long-term trends in gender, T-stage, subsite and treatment forlaryngeal cancer at a single center. Eur Arch Otorhinolaryngol.2014;271(12):3233-3239. doi:10.1007/s00405-014-3100-9
12. Fong PY, Tan SH, Lim DWT, et al. Association of clinical factorswith survival outcomes in laryngeal squamous cell carcinoma(LSCC). PLoS One. 2019;14(11):e0224665. doi:10.1371/journal.pone.0224665
13. Patel SG, Lydiatt WM, Glastonbury CM, et al. Larynx. Amin MB,ed, American Joint Committee on Cancer staging manual, 8thedn. NewYork: Springer; 2017.
14. Lewis CM, Chinn SB, Holsinger C, Weber RS. Cancer of theLarynx: Tis, T1, T2 Evaluation and Management. Bernier J, eds,Head and neck cancer multimodality management, 2nd edn.Switzerland: Springer; 2016.
15. Sharrett JM, Ward MC, Murray E, et al. Tumor volume usefulbeyond classic criteria in selecting larynx cancers for preservationtherapy. Laryngoscope. 2020;130(10):2372-2377. doi:10.1002/lary.28396
16. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiationwith or without concomitant chemotherapy for locally advancedhead and neck cancer. N Engl J Med. 2004;350(19):1945-1952.doi:10.1056/NEJMoa032641
Article available in :
Volume 4, Issue 4, 2023
Page : 315-322
https://doi.org/10.47582/jompac.1314922
Article Information
Received : 16 Haz 2023
Accepted : 15 Ağu 2023
Published : 30 Ağu 2023
Corresponding Author :

Ela Delikgöz Soykut: Department of Radiation Oncology, Samsun Training and Research Hospital, Samsun, Turkey

[email protected]
Citation : Delikgöz Soykut E, Odabaşı E, Sahin N, Baran A, Taban H, Unal A. Treatment selection for T4 laryngeal cancer: is organ- preserving approach possible with chemoradiotherapy or is multimodality treatment more effective?. J Med Palliat Care. 2023;4(4):315-322.

Read: 82
Cited: 0
Download : 89
_Footer